Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 1.62 USD 0.62% Market Closed
Market Cap: 431.1m USD

Autolus Therapeutics PLC
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Autolus Therapeutics PLC
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Autolus Therapeutics PLC
NASDAQ:AUTL
EPS (Diluted)
$0
CAGR 3-Years
22%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
EPS (Diluted)
-$2
CAGR 3-Years
26%
CAGR 5-Years
-103%
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
EPS (Diluted)
-$3
CAGR 3-Years
-2%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
EPS (Diluted)
-£1
CAGR 3-Years
31%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
EPS (Diluted)
£0
CAGR 3-Years
-23%
CAGR 5-Years
-12%
CAGR 10-Years
-8%
Oxford BioMedica PLC
LSE:OXB
EPS (Diluted)
£0
CAGR 3-Years
-10%
CAGR 5-Years
-17%
CAGR 10-Years
-6%
No Stocks Found

Autolus Therapeutics PLC
Glance View

Market Cap
431.1m USD
Industry
Biotechnology

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

AUTL Intrinsic Value
HIDDEN
Show

See Also

What is Autolus Therapeutics PLC's EPS (Diluted)?
EPS (Diluted)
-0.8 USD

Based on the financial report for Sep 30, 2025, Autolus Therapeutics PLC's EPS (Diluted) amounts to -0.8 USD.

What is Autolus Therapeutics PLC's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
21%

Over the last year, the EPS (Diluted) growth was -6%. The average annual EPS (Diluted) growth rates for Autolus Therapeutics PLC have been 22% over the past three years , 21% over the past five years .

Back to Top